S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
When Will the Next Bull Market Be?
The Charles Schwab Company Can Hit New Highs
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
Closing prices for crude oil, gold and other commodities
Retail sales surge 0.7% in March as Americans seem unfazed by higher prices with jobs plentiful
NASDAQ:SNY

Sanofi (SNY) Stock Price, News & Analysis

$46.24
+0.31 (+0.67%)
(As of 04/15/2024 ET)
Today's Range
$46.01
$46.90
50-Day Range
$45.75
$49.75
52-Week Range
$42.63
$57.82
Volume
2.00 million shs
Average Volume
1.82 million shs
Market Capitalization
$116.97 billion
P/E Ratio
19.59
Dividend Yield
2.98%
Price Target
$55.00

Sanofi MarketRank™ Stock Analysis

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
18.9% Upside
$55.00 Price Target
Short Interest
Healthy
0.16% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.94mentions of Sanofi in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.50%
From $4.16 to $4.68 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.27 out of 5 stars

Medical Sector

356th out of 928 stocks

Pharmaceutical Preparations Industry

159th out of 430 stocks

SNY stock logo

About Sanofi Stock (NASDAQ:SNY)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

SNY Stock Price History

SNY Stock News Headlines

Novo Nordisk Arms Wegovy to Be a Triple Threat (SNY)
Novo Nordisk has had success with Ozempic and Wegovy for Type 2 diabetes and obesity, seeks to expand indications to include cardio diseases and neuro disorders
Nerd Investor Reveals Secret To Make Money With A.I.
He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.
Nerd Investor Reveals Secret To Make Money With A.I.
He's doing something he's never done before. In ten years, this nerd investor has picked 210+ stocks that have gone up at least 100%.
Sanofi: BUY as FDA reviews Dupixent for COPD
SNY Quantitative Stock Analysis
Wall Street Lunch: Calhoun To Leave Boeing
See More Headlines
Receive SNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sanofi and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
4/16/2024
Next Earnings (Confirmed)
4/25/2024
Ex-Dividend for 6/6 Dividend
5/09/2024
Dividend Payable
6/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SNY
Employees
86,088
Year Founded
2004

Price Target and Rating

Average Stock Price Target
$55.00
High Stock Price Target
$55.00
Low Stock Price Target
$55.00
Potential Upside/Downside
+18.9%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$5.84 billion
Pretax Margin
15.40%

Debt

Sales & Book Value

Annual Sales
$46.61 billion
Cash Flow
$6.44 per share
Book Value
$31.81 per share

Miscellaneous

Outstanding Shares
2,529,610,000
Free Float
2,504,311,000
Market Cap
$116.97 billion
Optionable
Optionable
Beta
0.61

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Paul HudsonMr. Paul Hudson (Age 57)
    CEO & Director
    Comp: $4.07M
  • Mr. François-Xavier Roger (Age 62)
    Chief Financial Officer
  • Ms. Madeleine Roach (Age 40)
    Executive VP & Head of Business Operations
  • Mr. Laurent Gilhodes
    Principal Accounting Officer and Vice President of Corporate Accounting
  • Dr. Josephine Fubara
    Chief Science Officer of Consumer Health Care
  • Eva Schaefer-Jansen
    Head of Investor Relations
  • Mr. Dante Beccaria
    Global Compliance Officer & VP
  • Mr. Roy Papatheodorou (Age 46)
    Executive VP & General Counsel
  • Mr. Josep Catlla
    Head of Communications
  • Mr. Pierre Chancel (Age 67)
    Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing

Should I Buy Sanofi Stock? SNY Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in Sanofi:

  • Sanofi has a diverse portfolio of specialty care products, including DUPIXENT, which has shown promising results in treating various health conditions.
  • The company is actively engaged in research and development collaborations to develop novel small molecules for oncology and immunology, indicating a focus on innovation and future growth.
  • Sanofi's collaboration with various biotech companies for the development of antibody-based therapies and genome editing technologies showcases a commitment to staying at the forefront of healthcare advancements.
  • With a net margin of 12.56% and a return on equity of 27.47%, Sanofi demonstrates strong financial performance and efficiency in utilizing shareholder equity.
  • Analysts predict a positive EPS for the current year, indicating potential profitability and growth for investors.

Cons

Investors should be bearish about investing in Sanofi for these reasons:

  • Sanofi has received mixed analyst ratings recently, with downgrades from several firms, potentially signaling uncertainties or challenges in the company's performance or outlook.
  • The average rating of "Hold" and a consensus target price of $57.50 suggest a lack of strong buy recommendations, which may indicate limited short-term growth potential.
  • Market sentiment towards Sanofi may be impacted by the downgrade from "strong-buy" to "buy" by StockNews.com, potentially affecting investor confidence in the company's future prospects.
  • The company's stock price fluctuations and analyst rating changes could introduce volatility and uncertainty for investors, requiring a cautious approach to investment decisions.
  • Investors should closely monitor any further developments or news related to Sanofi to make informed decisions based on the evolving market landscape and industry dynamics.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, April 10, 2024. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

SNY Stock Analysis - Frequently Asked Questions

Should I buy or sell Sanofi stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNY, but not buy additional shares or sell existing shares.
View SNY analyst ratings
or view top-rated stocks.

What is Sanofi's stock price target for 2024?

6 Wall Street research analysts have issued 1 year price objectives for Sanofi's shares. Their SNY share price targets range from $55.00 to $55.00. On average, they predict the company's share price to reach $55.00 in the next year. This suggests a possible upside of 18.9% from the stock's current price.
View analysts price targets for SNY
or view top-rated stocks among Wall Street analysts.

How have SNY shares performed in 2024?

Sanofi's stock was trading at $49.73 on January 1st, 2024. Since then, SNY shares have decreased by 7.0% and is now trading at $46.24.
View the best growth stocks for 2024 here
.

When is Sanofi's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our SNY earnings forecast
.

How can I listen to Sanofi's earnings call?

Sanofi will be holding an earnings conference call on Thursday, April 25th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Sanofi's earnings last quarter?

Sanofi (NASDAQ:SNY) released its quarterly earnings data on Thursday, February, 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.94 by $0.05. The firm had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a trailing twelve-month return on equity of 27.47% and a net margin of 12.56%.

How often does Sanofi pay dividends? What is the dividend yield for Sanofi?

Sanofi announced an annual dividend on Tuesday, March 26th. Investors of record on Friday, May 10th will be paid a dividend of $1.478 per share on Thursday, June 6th. This represents a dividend yield of 2.98%. The ex-dividend date is Thursday, May 9th. This is an increase from the stock's previous annual dividend of $1.38.
Read our dividend analysis for SNY
.

Is Sanofi a good dividend stock?

Sanofi (NASDAQ:SNY) pays an annual dividend of $1.38 per share and currently has a dividend yield of 2.99%. The company has been increasing its dividend for 2 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 58.47%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, SNY will have a dividend payout ratio of 29.49% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for SNY.

What is Paul Hudson's approval rating as Sanofi's CEO?

277 employees have rated Sanofi Chief Executive Officer Paul Hudson on Glassdoor.com. Paul Hudson has an approval rating of 94% among the company's employees. This puts Paul Hudson in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Sanofi own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include AbbVie (ABBV), Abbott Laboratories (ABT), Adobe (ADBE), Amgen (AMGN), Broadcom (AVGO), Boeing (BA), Alibaba Group (BABA), Bank of America (BAC) and BP (BP).

Who are Sanofi's major shareholders?

Sanofi's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Foundation Resource Management Inc. (0.01%), CWM LLC (0.01%), First Hawaiian Bank (0.01%), Thomasville National Bank (0.00%), Cardinal Capital Management (0.00%) and Park Avenue Securities LLC (0.00%).
View institutional ownership trends
.

How do I buy shares of Sanofi?

Shares of SNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Sanofi have any subsidiaries?
The following companies are subsidiares of Sanofi: A. Nattermann & Cie. GmbH, AO Sanofi Russia, Ablynx, Ablynx N.V., Allston Landing Limited Partnership, Aventis Inc., Aventis Pharma (Manufacturing) Pte. Ltd, Aventis Pharma Limited, Aventis Pharma S.A., Aventis S.A., Aventisub LLC, Bioverativ, Bioverativ Inc., Bioverativ Therapeutics Inc., Bioverativ U.S.LLC, Carraig Insurance DAC, Chattem Inc., Chinoin Private Co. Ltd, Francopia, Genfar S.A., Genzyme Corporation, Genzyme Europe B.V., Genzyme Flanders BVBA, Genzyme Global Sarl, Genzyme Ireland Limited, Genzyme Limited, Genzyme Polyclonals SAS, Genzyme Therapeutic Products Limited Partnership, Genzyme Therapeutics Limited, Genzyme de Argentina S.A., Hoechst GmbH, Kiadis Pharma, Limited Liability Company Sanofi-Aventis Ukraine, PT Aventis Pharma, Principia BioPharma, SSP Co. Ltd, Sanofi (Beijing) Pharmaceuticals Co.Ltd, Sanofi (China) Investment Co. Ltd, Sanofi (Hangzhou) Pharmaceuticals Co. Ltd, Sanofi A/S, Sanofi AB, Sanofi Arabia Trading Company Limited, Sanofi Aventis NA Holding Inc., Sanofi Belgium, Sanofi Biotechnology, Sanofi Chimie, Sanofi Egypt, Sanofi Finance Ireland limited, Sanofi Foreign Participations B.V., Sanofi Healthcare India Private Limited, Sanofi Ilac Sanayi ve Ticaret A.S., Sanofi India Limited, Sanofi K.K., Sanofi Mature IP, Sanofi Medley Farmaceutica Ltda, Sanofi Nichi-Iko K.K., Sanofi Oy, Sanofi Pasteur, Sanofi Pasteur Asi Ticaret A.S., Sanofi Pasteur Biologies Co. Ltd, Sanofi Pasteur Europe, Sanofi Pasteur Inc., Sanofi Pasteur India Private Ltd, Sanofi Pasteur Limited, Sanofi Pasteur Ltd, Sanofi Pasteur NVL, Sanofi Pasteur S.A. de C.V., Sanofi Produtos Farmaceuticos Lda, Sanofi Romania SRL, Sanofi S.p.A., Sanofi Saglik Urunleri Limited Sirketi, Sanofi Taiwan Co. Ltd, Sanofi US Corporation, Sanofi US Services Inc., Sanofi Vaccine Technologies, Sanofi Winthrop Industrie, Sanofi-Aventis (Malaysia) SDN. BHD., Sanofi-Aventis (Suisse) SA, Sanofi-Aventis (Thailand) Ltd, Sanofi-Aventis A.E.B.E., Sanofi-Aventis Algérie, Sanofi-Aventis Argentina S.A., Sanofi-Aventis Australia Pty Ltd, Sanofi-Aventis Canada Inc., Sanofi-Aventis Deutschland GmbH, Sanofi-Aventis France, Sanofi-Aventis GmbH, Sanofi-Aventis Groupe, Sanofi-Aventis Gulf FZE, Sanofi-Aventis Healthcare Pty Ltd, Sanofi-Aventis Hong-Kong Limited, Sanofi-Aventis Ireland Ltd, Sanofi-Aventis Israël Ltd, Sanofi-Aventis Korea Co. Ltd, Sanofi-Aventis Liban s.a.l., Sanofi-Aventis Maroc, Sanofi-Aventis Netherlands B.V., Sanofi-Aventis Norge AS, Sanofi-Aventis Pakistan Limited, Sanofi-Aventis Participations, Sanofi-Aventis Philippines Inc., Sanofi-Aventis Private Co Ltd, Sanofi-Aventis Recherche & Développement, Sanofi-Aventis S.A., Sanofi-Aventis Singapore Pte. Ltd, Sanofi-Aventis South Africa (Pty) Ltd, Sanofi-Aventis Sp. z.o.o., Sanofi-Aventis U.S. LLC, Sanofi-Aventis UK Holdings Limited, Sanofi-Aventis Winthrop S.A. de C.V., Sanofi-Aventis de Colombia S.A., Sanofi-Aventis de Mexico S.A. de C.V., Sanofi-Aventis de Panama S.A., Sanofi-Aventis de Venezuela S.A., Sanofi-Aventis del Ecuador S.A., Sanofi-Aventis del Peru S.A., Sanofi-Aventis s.r.o., Sanofi-Synthelabo (India) Private Ltd, Sanofi-aventis Vietnam Company Limited, Shenzhen Sanofi pasteur Biological Products Co Ltd, Synthorx, VaxServe Inc., sanofi-aventis Puerto Rico Inc, and sanofi-aventis Slovakia s.r.o..
Read More
This page (NASDAQ:SNY) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners